Diabetes Devices (CGM & Insulin Delivery)

Medtronic reported first-quarter fiscal 2027 revenue of $9.76 billion, up 13.7% from a year earlier, and raised its full-year outlook, with adjusted diluted EPS climbing 15.1% to $1.45 and GAAP EPS rising 40.7% to $1.14. Management now expects organic revenue growth of 7.25%-7.75% for fiscal 2027, up from 6.75%-7.25% previously, and lifted adjusted EPS guidance to $5.94-$6.00. The quarter included an extra selling week that added about $570 million to revenue, so the headline growth rate should not be expected to repeat. Cardiovascular delivered strong growth, while Neuroscience, Medical Surgical and Diabetes also posted high-single-digit or double-digit organic growth. At a share price of around $89-$90, the stock trades at roughly 15 times the midpoint of the adjusted EPS forecast, versus about 22 times trailing earnings, while paying a quarterly dividend of $0.72 per share, or $2.88 a year, for a yield of roughly 3.2%-3.3%. Medtronic is also expanding its Affera cardiac mapping and ablation system, investing in Pi-Cardia and Cornerstone Robotics, and has acquired Scientia Vascular and SPR Therapeutics, with a planned separation of its Diabetes business.

Novo Nordisk will shorten its name to Novo and update its logo, with its trademark bull shifting to face right, as the Danish drugmaker battles Eli Lilly for dominance in the obesity-drug market. CEO Mike Doustdar is pushing to make Novo leaner and more competitive, and the company will detail its updated corporate strategy at a Capital Markets Day on September 21 in London. Separately, Eli Lilly said the U.S. FDA granted full approval for an all-oral regimen combining its estrogen receptor antagonist Inluriyo and kinase inhibitor Verzenio as a late-line option for adults with estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation whose disease progressed after one or more prior endocrine therapies. GE HealthCare Technologies is in advanced talks to acquire Sofie Biosciences for about $1 billion, a deal that would expand its presence in radioactive diagnostic agents used with medical scans, according to the Financial Times. Summit Therapeutics said ivonescimab reduced the risk of death by 27% versus Merck's Keytruda in a late-stage lung cancer trial, with median overall survival of 30.8 months versus 22.6 months. Medtronic launched an exchange offer to split off at least 80.1% of MiniMed Group, allowing shareholders to exchange ordinary shares for MiniMed common stock at a 7% discount.

Beta Bionics announced plans for an underwritten public offering of $125M of common stock. The company also intends to grant underwriters a 30-day option to purchase up to an additional $18.75M of common stock. Beta Bionics expects to use the net proceeds for general corporate purposes, including commercialization of Mint, manufacturing expansion, research and development, clinical development and working capital. Funds may also support product enhancements and potential strategic opportunities, alongside operating expenses. BBNX shares fell 8% in post-market trading.

Medtronic plc reported fiscal first-quarter 2027 revenue of nearly $9.8 billion, up 13.7% organically, while non-GAAP diluted EPS rose 15.1% to $1.45. The company raised its full-year organic revenue-growth forecast to 7.25%-7.75% from 6.75%-7.25% and lifted the lower end of its non-GAAP diluted EPS guidance to $5.94 from $5.90. Cardiovascular revenue increased 18.9% organically to $3.927 billion, with Cardiac Ablation Solutions up 88%, while Neuroscience grew 9.3% and Medical Surgical increased 10.2%. The quarter included an extra fiscal week that Medtronic estimates benefited organic growth by approximately $570 million, and non-GAAP operating margin rose only 10 basis points to 23.7%. Medtronic also committed $700 million to Cornerstone Robotics for distribution rights to its Sentire surgical system in select markets outside the United States and agreed to invest up to $80 million in Pi-Cardia, with an option to acquire the company for up to $210 million, as it proceeds with the separation of its diabetes division by the end of the year.

Implicity has received FDA 510(k) clearance for its next-generation ILR ECG Analyzer, a cloud-based AI algorithm that reduces false-positive alerts from implantable cardiac monitors by up to 76% while maintaining high sensitivity for true events. The software works as a manufacturer-agnostic second layer on top of initial device filters, supporting monitors from Abbott, Biotronik, Boston Scientific, and Medtronic. Research published in EP Europace and Heart Rhythm demonstrated the algorithm's performance, and a 2026 multicenter study in JACC: Clinical Electrophysiology highlighted the ongoing burden of false-positive alerts across vendors, underscoring the need for such improvements. Implicity expects the analyzer to become commercially available to U.S. customers in the coming months.

Tonghua Dongbao announced that its Insulin Aspart Injection, co-developed with Nanjing King-Friend Biochemical Pharmaceutical, has officially received marketing approval from the US Food and Drug Administration for improving glycemic control in adult and pediatric patients with diabetes.

Penumbra received FDA clearance for its THUNDERBOLT computer-assisted vacuum thrombectomy system for acute ischemic stroke treatment. The clearance follows the THUNDER study, which reported strong safety and efficacy results for the device. A leading stroke center has already begun using THUNDERBOLT in clinical practice, expanding its real-world footprint. The system uses computer-assisted, modulated aspiration to automate part of the thrombectomy process, potentially offering hospitals more consistent clot removal and procedure times. Penumbra, traded on the NYSE under ticker PEN, focuses on medical devices for neuro and vascular conditions, and this clearance adds a new technology to its stroke portfolio at a time when hospitals seek more precise and efficient treatment tools.

Biotechnology and pharmaceutical IPOs have generated a weighted average return of 55% in the U.S. market this year, sharply outperforming the broader market's 4.4% weighted average loss, according to Bloomberg data through July 17. The strong performance is drawing more drug developers to go public, with at least six filing this month, led by Scribe Therapeutics, and the number of completed biotech IPOs in 2026 already surpassing last year's total while proceeds exceed $5 billion, roughly three times the prior year's amount. Parabilis Medicines raised $770.6 million in the largest biotech IPO on record, and Veradermics has gained more than 500% since its February debut, making it the best-performing U.S. IPO across all sectors. The sector's recovery is supported by a 13% gain in the Nasdaq Biotechnology Index, a stable regulatory environment, and renewed acquisition activity, including three deals valued at $10 billion or more announced in the past month involving AbbVie, GSK, and Vertex Pharmaceuticals. Investment bankers note that major fund groups are reallocating capital toward healthcare, though higher interest rates could pose a headwind.

Novo Nordisk and Fangzhou have launched Kyinsu, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, in China through Fangzhou's AI-driven Internet hospital. The launch expands Novo Nordisk's presence in China by pairing a new treatment format with a digital care platform, targeting broader access for people living with diabetes. The partnership may influence how Novo Nordisk allocates capital between traditional channels and online care in large markets, while also testing a go-to-market model that ties the drug to a digital ecosystem for diagnosis, titration, adherence, and follow-up at scale. Analysts flag potential earnings pressure from competition and pricing, as well as operational and regulatory risks tied to the partner's AI and Internet-hospital infrastructure. Investors may watch how quickly Kyinsu uptake builds on Fangzhou's platform and whether Novo Nordisk extends similar digital-first launches to other products or markets.

APP signals a bright second half of 2026, accelerating revenue recognition from its backlog continuously, while benefiting from new car models gradually entering production lines in the third and fourth quarters. The company is also pushing forward with 3D metal printing to penetrate the personalized medical device market, partnering with Lerdsin Hospital to develop high-precision titanium parts. Chief Operating Officer Krikkrit Jearakamolchuen revealed that in the second quarter, the company was able to accelerate delivery of its order book well, although compared to the same period last year, there may be a difference due to the high revenue base from the previous year's low-volume production work for a subsidiary on a large-scale project. For the automotive business, APP remains strong in producing interior parts, especially plastic components such as seating systems and front consoles, supporting both internal combustion engine and electric vehicles. The company positions itself as a Tier 2 parts manufacturer, acting as a behind-the-scenes supporter for all Tier 1 manufacturers, reducing the risk of relying on a single customer and opening opportunities to supply parts to every car brand. In the medical business, the company is advancing 3D metal printing technology in collaboration with Lerdsin Hospital, a center for orthopedics, aiming to produce implantable devices from titanium metal, such as cranial plates and personalized medical devices requiring high precision. Additionally, the company continues to use a cross-product selling strategy to increase sales value from its existing customer base, while studying expansion into the defense industry and industrial automation systems, which are currently under discussion with partners and in the project development pipeline.